US Stock MarketDetailed Quotes

UTHR United Therapeutics

Watchlist
  • 370.580
  • +0.140+0.04%
Close Feb 14 16:00 ET
  • 370.580
  • 0.0000.00%
Post 20:01 ET
16.54BMarket Cap16.28P/E (TTM)

About United Therapeutics Company

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. The company was founded by Martine A. Rothblatt on June 26, 1996 and is headquartered in Silver Spring, MD.

Company Profile

SymbolUTHR
Company NameUnited Therapeutics
Listing DateJun 17, 1999
Issue Price12.00
Founded1996
CEODr. Martine A. Rothblatt, J.D.,M.B.A.,PhD
MarketNASDAQ
Employees1168
Fiscal Year Ends12-31
Address1000 Spring Street
CitySilver Spring
ProvinceMaryland
CountryUnited States of America
Zip Code20910
Phone1-301-608-9292

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Martine A. Rothblatt, J.D.,M.B.A.,PhD
  • Chairperson of the Board Chief Executive Officer
  • 16.96M
  • James C. Edgemond
  • Chief Financial Officer, Principal Accounting Officer and Treasurer
  • 6.05M
  • Michael Benkowitz
  • President and Chief Operating Officer
  • 9.81M
  • Paul A. Mahon,J.D.
  • Executive Vice President, General Counsel and Corporate Secretary
  • 5.15M
  • Christopher Patusky,J.D.
  • Vice Chairman of the Board and Lead Independent Director
  • 532.60K
  • Governor Tommy G. Thompson
  • Independent Director
  • 456.54K
  • Dr. Judy D. Olian, PhD
  • Independent Director
  • 488.66K
  • Nilda Mesa, J.D.
  • Independent Director
  • 487.60K
  • Richard Giltner
  • Independent Director
  • 513.66K
  • Dr. Louis W. Sullivan, M.D.
  • Independent Director
  • 471.54K
  • Christopher Causey,M.B.A.
  • Independent Director
  • 481.54K
  • Jan Malcolm
  • Independent Director
  • --
  • Raymond Dwek,F.R.S.
  • Independent Director
  • 456.54K
  • Raymond C. Kurzweil
  • Independent Director
  • 457.60K
  • Dr. Linda Maxwell, M.B.A.,M.D.
  • Independent Director
  • 456.54K

Trending Stocks

Reassessing Chinese Assets
Following the introduction of China's groundbreaking DeepSeek technology, Wall Street giants have revised their investment outlooks for the Chinese market.
Discussing
Tesla's earnings caused fluctuations, what's your market outlook?
Tesla's Q4 2024 revenue was $25.71 billion, up 2% year-on-year but below expectations. Can Tesla's stock price keep rising in 2025 with Trum Show More